Reputation Now Sits At The Leadership Table

Reputation is no longer built by words alone, but through consistent decisions, responsible governance, and leadership behavior over time.

Why The IFRS-GRI Alliance Is A Game-Changer For Corporate Disclosures

With IFRS and GRI working together, companies can build stronger reporting systems that serve both investor needs and broader public accountability.

Real-Life Education Made Simple: STI Adopts DepEd’s Enhanced SHS Program To Introduce Flexible Electives

STI’s Education for Real Life philosophy continues with a program designed to help students learn with clearer purpose.

The 2027 ESG Mandate: BSP’s Sustainability Reporting Rollout For Philippine Banks

Philippine banks are preparing for a phased ESG reporting mandate as the BSP moves to strengthen climate-related disclosures and financial system resilience.

Economic Czar Urges NGAs To Ease Processes For Pharma Investors

Secretary Frederick Go urges national government agencies to resolve issues in the pharmaceutical industry and strengthen healthcare manufacturing.

Economic Czar Urges NGAs To Ease Processes For Pharma Investors

810
810

How do you feel about this story?

Like
Love
Haha
Wow
Sad
Angry

Special Assistant to the President for Investment and Economic Affairs Secretary Frederick Go urged concerned national government agencies (NGAs) to address the “pain points” of pharmaceutical industry players and strengthen the country’s manufacturing of healthcare products.

In his speech delivered by Undersecretary Jose Edwinel Guilas, during a joint briefing of the Anti-Red Tape Authority, Department of Health, Philippine Economic Zone Authority and Food and Drug Administration (FDA) in Quezon City on Monday, Go urged the agencies to ease the processes for pharma players.

President Ferdinand R. Marcos Jr.’s economic czar mentioned that the so-called pain points for medical drug and device manufacturers are the bureaucratic nature of existing policies of regulatory agencies; difficulty in exporting and importing medicine; and the difficulty of international pharma companies in investing in the Philippines.

“Can we not consider the certificates of other countries with higher certifying standards as compliance with ours?” Go said, adding that it will also address FDA’s lack of manpower and equipment.

For import and export processes, Go said an administrative order is underway to resolve the challenge.

To ease doing business for investors, the government is eyeing an exclusive ecozone for pharma manufacturing.

“Our office, together with the Philippine Economic Zone Authority, and FDA has called a technical working group to make it easier for pharmaceutical companies to set up their operations in economic zones,” Go added. (PNA)